PTC Therapeutics (PTCT) to Release Quarterly Earnings on Thursday

Key Points

• PTC Therapeutics is set to release its Q2 2025 earnings on Thursday, August 7th, with analysts expecting earnings of ($1.07) per share and revenue of $173.01 million.
• In its last quarterly earnings, PTC Therapeutics reported a significant earnings beat with $10.04 EPS, far exceeding analyst expectations of $0.85.
• Analysts have varying opinions on PTC Therapeutics, with price targets ranging from $50.00 to $120.00, reflecting a consensus rating of "Moderate Buy".

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect PTC Therapeutics to post earnings of ($1.07) per share and revenue of $173.01 million for the quarter. PTC Therapeutics has set its FY 2025 guidance at EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The firm had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. During the same quarter in the previous year, the business earned ($1.20) EPS. The company's quarterly revenue was down 9.6% on a year-over-year basis. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PTC Therapeutics Trading Up 0.0%

Shares of PTCT stock traded up $0.02 on Friday, reaching $52.13. 1,020,621 shares of the company's stock were exchanged, compared to its average volume of 1,123,253. The company's fifty day simple moving average is $49.21 and its 200 day simple moving average is $48.71. PTC Therapeutics has a 52 week low of $29.01 and a 52 week high of $58.38. The stock has a market capitalization of $4.13 billion, a PE ratio of 8.01 and a beta of 0.54.

Insider Activity

In related news, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total transaction of $124,441.36. Following the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at $3,557,163.20. This represents a 3.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Mark Elliott Boulding sold 1,929 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $46.18, for a total value of $89,081.22. Following the transaction, the vice president directly owned 103,901 shares in the company, valued at $4,798,148.18. This represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,328 shares of company stock worth $254,158 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of PTC Therapeutics

A hedge fund recently bought a new stake in PTC Therapeutics stock. Empowered Funds LLC bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 39,228 shares of the biopharmaceutical company's stock, valued at approximately $1,999,000.

Analyst Ratings Changes

PTCT has been the subject of a number of recent analyst reports. Wall Street Zen cut PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 16th. Barclays lifted their target price on PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a research report on Tuesday. Truist Financial lifted their target price on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday. Wells Fargo & Company lifted their target price on PTC Therapeutics from $74.00 to $78.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, UBS Group lifted their target price on PTC Therapeutics from $71.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $69.38.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.